Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2019-05-10 Board/Management Inform…
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges announcing the outcome of a Board Meeting held on May 10, 2019. The content specifically relates to the re-appointment of Independent Directors for a second term, subject to shareholder approval at the upcoming AGM. There are no financial statements, audit details, or other report contents. The document is an announcement about board/management changes rather than a full report or presentation. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming this classification with high confidence.
2019-05-10 English
Dividend
Notice of Dividend Amount Classification · 100% confidence The document is a short announcement dated May 10, 2019, from Strides Pharma Science Limited addressed to stock exchanges. It communicates the outcome of a board meeting specifically about the recommendation of a final dividend for the fiscal year ended March 31, 2019. The text states the dividend percentage and amount per share and mentions the payment timeline contingent on shareholder approval at the upcoming AGM. There are no financial statements or detailed financial data included, only a dividend declaration. This fits the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts and payment details to shareholders.
2019-05-10 English
Financial Result Updates
Regulatory Filings
2019-05-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Earnings Release Classification · 90% confidence The document is a notification about an upcoming earnings call to discuss the audited financial results for the quarter/year ended March 31, 2019. It provides details for the conference call but does not contain the financial results themselves or a transcript of the call. The document is short (2208 characters) and serves as an announcement for the earnings call rather than the earnings release or call transcript itself. Therefore, it fits best under the category of Earnings Release (ER) as an initial announcement of quarterly/periodical financial results discussion. FY 2019
2019-05-08 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short communication from Strides Pharma Science Limited informing stock exchanges about the USFDA classification of their Puducherry facility as Official Action Initiated (OAI) following an inspection. It mentions the impact on pending ANDA approvals and references an upcoming earnings call for further updates. The document is brief (1640 characters), serves as an announcement of a regulatory development, and does not contain financial statements or detailed analysis. It is not a full report, earnings release, or management discussion. It is an informational regulatory announcement related to compliance and inspection outcomes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-05-06 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notification letter addressed to stock exchanges informing about an upcoming Board Meeting scheduled for May 10, 2019, to consider and approve the audited financial results for the quarter and year ended March 31, 2019. It also mentions the closure of the trading window for insiders around the announcement date. The document does not contain the actual financial results or detailed financial data but is an announcement of the meeting where such results will be considered and approved. The document length is short (1765 characters), and it serves as a notice rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than an Annual Report (10-K) or Earnings Release (ER).
2019-05-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.